Degenerative mitral valve regurgitation: best practice revolution

Degenerative mitral valve disease often leads to leaflet prolapse due to chordal elongation or rupture, and resulting in mitral valve regurgitation. Guideline referral for surgical intervention centres primarily on symptoms and ventricular dysfunction. The recommended treatment for degenerative mitral valve disease is mitral valve reconstruction, as opposed to valve replacement with a bioprosthetic or mechanical valve, because valve repair is associated with improved event free survival. Recent studies have documented a significant number of patients are not referred in a timely fashion according to established guidelines, and when they are subjected to surgery, an alarming number of patients continue to undergo mitral valve replacement. The debate around appropriate timing of intervention for asymptomatic severe mitral valve regurgitation has put additional emphasis on targeted surgeon referral and the need to ensure a very high rate of mitral valve repair, particularly in the non-elderly population. Current clinical practice remains suboptimal for many patients, and this review explores the need for a ‘best practice revolution’ in the field of degenerative mitral valve regurgitation

Le operazioni di Borsa : secondo La practica, la legge e l'economia politica con appendici contenenti un piccolo Dizionario dei termini più usati in materia di Borsa, i Regolamenti delle principali Borse di commercio italiane e le Leggi relative alla pubblica mediazione / David Supino

FA163[8], 234 p

Le operazioni di Borsa : secondo La practica, la legge e l'economia politica con appendici contenenti un piccolo Dizionario dei termini più usati in materia di Borsa, i Regolamenti delle principali Borse di commercio italiane e le Leggi relative alla pubblica mediazione / David Supino

FA163[8], 234 p

The Powers of Shareholders of a Societe Anonyme

French corporation law,which is primarily statutory, has seen no comprehensive statutory revision in almost a century; and while literally dozens of amendments have been engrafted on to the basic corporate legislation of 1867, they are for the most part ad hoc legislative resolutions of particular problems which betray no underlying unity of design and which have broken the unity of the old legislation. The result is that the law is Janus faced, and the theories which the law embodies are not wholly in accord with social and economic needs. In this necessary process of assimilating new insights into the law the French courts have a potentially important role. It is true that the courts are said to exercise only a very limited law making power:they are required to decide cases in terms of law, which means statutory law. Yet no statute can be so well drafted as to be comprehensive, and gaps inevitably appear. Faced with the need both to create law and to avoid the charge of usurping legislative power, the courts have had resort to the spirit of the code in order to resolve disputes on which the legislature has not passed. But such a rationalization becomes unacceptable when the code is shown to have no unity of design, and when the spirit, insofar as it is existent, would dictate an inexpedient result. Thus there is born the attempt, particularly on the part of the commentators, to construct conceptual theories that will harmonize the seemingly discordant pattern of the law and will allow the courts to produce or justify what is felt to bean acceptable result. It is the purpose of this essay to study one small facet of this process of adaptation and change; to attempt to achieve some under-standing of the French law governing the relation of the shareholders to the societ anonyme, the French analogue of the corporation

Il Diritto commerciale : rivista periodica e critica di giurisprudenza e di legislazione.

"Con una parte dedicata al diritto aeronautico," 1926-Published in Pisa, 1883-1909; Torino, 1910-1920; Genova, 1921-Editors: 1883-1909, David Supino (with Filippo Serafini, 1883-1897; Pietro Cogliolo, 1910- , Luigi Parodi, 1921- )Subtitle varies: -<1938>, Rivista mensile critica di dottrina, legislazione e giurisprudenza.Title varies: 1921-<1938> Diritto commerciale e la parte generale delle obbligazioni.Vols. 28-29 published 1910.Vols. 28-59 called Serie seconda, v. 1-32.Mode of access: Internet

Derecho Mercantil de Supino; traducido de la cuarta edición y anotado extensamente con las diferencias...

Ante

The long Pentraxin PTX3 serves as an early predictive biomarker of co-infections in COVID-19Research in context

Summary: Background: COVID-19 clinical course is highly variable and secondary infections contribute to COVID-19 complexity. Early detection of secondary infections is clinically relevant for patient outcome. Procalcitonin (PCT) and C-reactive protein (CRP) are the most used biomarkers of infections. Pentraxin 3 (PTX3) is an acute phase protein with promising performance as early biomarker in infections. In patients with COVID-19, PTX3 plasma concentrations at hospital admission are independent predictor of poor outcome. In this study, we assessed whether PTX3 contributes to early identification of co-infections during the course of COVID-19. Methods: We analyzed PTX3 levels in patients affected by COVID-19 with (n = 101) or without (n = 179) community or hospital-acquired fungal or bacterial secondary infections (CAIs or HAIs). Findings: PTX3 plasma concentrations at diagnosis of CAI or HAI were significantly higher than those in patients without secondary infections. Compared to PCT and CRP, the increase of PTX3 plasma levels was associated with the highest hazard ratio for CAIs and HAIs (aHR 11.68 and 24.90). In multivariable Cox regression analysis, PTX3 was also the most significant predictor of 28-days mortality or intensive care unit admission of patients with potential co-infections, faring more pronounced than CRP and PCT. Interpretation: PTX3 is a promising predictive biomarker for early identification and risk stratification of patients with COVID-19 and co-infections. Funding: Dolce &amp; Gabbana fashion house donation; Ministero della Salute for COVID-19; EU funding within the MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT) and MUR PNRR Italian network of excellence for advanced diagnosis (Project no. PNC-E3-2022-23683266 PNC-HLS-DA); EU MSCA (project CORVOS 860044)